drugset / Trial / NCT06494527
A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults
Phase 1
Active not recruiting
30 enrolled
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and PK/PD profiles of RG002C0106 injection in healthy adult subjects. The study will be divided into the following parts: Part A, conducted : SAD stage Part B, conducted: MAD stage
Timeline
- Start
- 2024-10-18
- Primary completion
- 2026-08-20
- Completion
- 2026-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RG002C0106 | Small interfering RNA (siRNA) | 25 mg | Subcutaneous |
Indications
No indication recorded.